AVENTIS PHARMACEUTICALS PRODUCTS INC.
Patent Owner
Stats
- 11 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- May 27, 2003 most recent publication
Details
- 11 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,311 Total Citation Count
- Jun 23, 1986 Earliest Filing
- 30 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
6555328 Screening methods for altering circadian rhythms and for human casein kinase I .delta. and/or .epsilon. phosphorylation of human clock proteins, period 1, -2 and -3Jun 07, 00Apr 29, 03[C12Q]
RE37650 Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseFeb 02, 00Apr 09, 02[A61K]
6034093 Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compoundsAug 06, 98Mar 07, 00[A61K, C07D]
5958918 Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-?(aminominomethyl)phenylalkyl!-azaheterocyclylamide compoundsNov 21, 97Sep 28, 99[A61K, C07D]
5912365 Derivatives of 2-azabicyclo?2.2.1! heptane, their preparation and their applicationAug 19, 97Jun 15, 99[C07D]
5731315 Substituted sulfonic acid n-?(aminoiminomethyl)phenylalkyl!-azaheterocyclamide compoundsDec 06, 96Mar 24, 98[A61K, C07D]
5714493 Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseJun 04, 96Feb 03, 98[A61K]
5710158 Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseApr 19, 94Jan 20, 98[A61K, C07D]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2002/0146,829 Neutral and anionic colloidal particles for gene deliveryAbandonedNov 29, 01Oct 10, 02[A61K, C12N]
2002/0013,310 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compoundsAbandonedJul 30, 01Jan 31, 02[A61K, C07D]
6281227 Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compoundsExpiredDec 02, 99Aug 28, 01[A61K, C07D]
6274705 Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptidesExpiredAug 21, 98Aug 14, 01[C07K]
6235909 Preparation of is-[1A,2B,3B,4A(S*)]-4-[7-[[1-(3-chloro-2-Thienyl)methyl]amino]-3H-imidazo [4,5-B]pyridin-3-YL]-N-ethyl-2,3-dihydroxycyclopentanecarboxamideExpiredJul 28, 00May 22, 01[C07D]
6159978 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56.sup.lck tyrosine kinasesExpiredNov 24, 98Dec 12, 00[A61K, C07D]
6153588 Stable non-hygroscopic crystalline form of N-[N-[N-4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] aspartyl]-L-.beta.-cyclohexyl alanine amideExpiredFeb 18, 99Nov 28, 00[A61K, C07K]
6153597 Pharmaceutical composition useful for nucleic acid transfection, and use thereofExpiredMar 27, 98Nov 28, 00[A61K]
6143508 Device and process for cell capture and recoveryExpiredJun 07, 95Nov 07, 00[A61K, C12N, C07K]
6143894 Preparation of [1S-[1A,2B,3B,4A(S*)]]-4-[7-[[1-(3-chloro-2-thienyl)methyl propyl]amino] -3H-imidazo[4,5-B]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxa mideExpiredJan 19, 99Nov 07, 00[C07D]
6127550 Stereospecific preparation of chiral 1-aryl-and 1-heteroaryl-2-substituted ethyl-2-aminesExpiredMar 11, 99Oct 03, 00[C07D, C07C]
5736554 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesExpiredMay 31, 95Apr 07, 98[A61K, C07D]
5652366 DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereofExpiredJun 07, 95Jul 29, 97[C07D]
5561134 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesExpiredOct 03, 94Oct 01, 96[A61K, C07D]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
